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ExtEndEd rEport
Identification of a transitional fibroblast function in 
very early rheumatoid arthritis
Andrew Filer,1,2 Lewis S C Ward,1 Samuel Kemble,1 Christopher S davies,3 
Hafsa Munir,4 rebekah rogers,1 Karim raza,1,2 Christopher dominic Buckley,1,2 
Gerard B nash,4 Helen M McGettrick1
ABstrAct
Objectives Synovial fibroblasts actively regulate 
the inflammatory infiltrate by communicating with 
neighbouring endothelial cells (EC). Surprisingly, little 
is known about how the development of rheumatoid 
arthritis (rA) alters these immunomodulatory properties. 
We examined the effects of phase of rA and disease 
outcome (resolving vs persistence) on fibroblast crosstalk 
with EC and regulation of lymphocyte recruitment.
Methods Fibroblasts were isolated from patients 
without synovitis, with resolving arthritis, very early 
rA (VerA; symptom ≤12 weeks) and established rA 
undergoing joint replacement (Jrep) surgery. Endothelial-
fibroblast cocultures were formed on opposite sides of 
porous filters. Lymphocyte adhesion from flow, secretion 
of soluble mediators and interleukin 6 (IL-6) signalling 
were assessed.
results Fibroblasts from non-inflamed and resolving 
arthritis were immunosuppressive, inhibiting lymphocyte 
recruitment to cytokine-treated endothelium. this 
effect was lost very early in the development of rA, 
such that fibroblasts no longer suppressed recruitment. 
Changes in IL-6 and transforming growth factor beta 
1 (tGF-β1) signalling appeared critical for the loss of 
the immunosuppressive phenotype. In the absence of 
exogenous cytokines, Jrep, but not VerA, fibroblasts 
activated endothelium to support lymphocyte.
conclusions In rA, fibroblasts undergo two distinct 
changes in function: first a loss of immunosuppressive 
responses early in disease development, followed by the 
later acquisition of a stimulatory phenotype. Fibroblasts 
exhibit a transitional functional phenotype during the 
first 3 months of symptoms that contributes to the 
accumulation of persistent infiltrates. Finally, the role 
of IL-6 and tGF-β1 changes from immunosuppressive 
in resolving arthritis to stimulatory very early in the 
development of rA. Early interventions targeting 
’pathogenic’ fibroblasts may be required in order to 
restore protective regulatory processes.
IntrOductIOn
Fibroblasts are a type of mesenchymal stromal 
cell with immunomodulatory capabilities.1 They 
display distinct spatial identities2 3 that govern their 
behaviour and allow them to establish tissue-spe-
cific ‘address-codes’.4 It is these address codes that 
actively regulate the recruitment of leucocytes to 
inflamed sites and their subsequent behaviour.1 
Fibroblasts achieve these effects in part by 
conversing with neighbouring vascular endothelial 
cells (EC) to regulate leucocyte adhesion.1 We have 
previously reported that dermal fibroblasts potently 
downregulate the responsiveness of EC to cyto-
kines, suppressing lymphocyte recruitment in an 
interleukin 6 (IL-6) and transforming growth factor 
beta 1 (TGF-β1) dependent manner.5 Consequently, 
each inflammatory response is contextual, defined 
by the phenotype of the local fibroblast population.
In rheumatoid arthritis (RA), the stable repro-
gramming of synovial fibroblasts disrupts their 
protective regulatory processes, promoting their 
survival and enhancing their production of proin-
flammatory agents and proteases for example.6 
Additionally, rheumatoid synovial fibroblasts invade 
human cartilage in an severe combined immuno-
deficiency (SCID) model of arthritis7 8 and appear 
to display tropism for damaged tissue, migrating 
to distant cell-free cartilage in vivo, potentially 
‘spreading’ disease.9 This pathogenic phenotype 
causes RA fibroblasts to bypass many of the regu-
latory checkpoints that coordinate the successful 
resolution of an inflammatory episode. Indeed, we 
have shown that rheumatoid synovial fibroblasts 
activate endothelium to inappropriately recruit 
leucocytes,5 10 while simultaneously blocking leuco-
cyte apoptosis.11 Thus, rheumatoid synovial fibro-
blasts are capable of generating and supporting 
persistent leucocyte infiltrates.
Fibroblasts are endogenous regulators of inflam-
mation, and in our hands demonstrate a spec-
trum of responses, ranging from suppression of 
cytokine-induced responses to stimulation of a 
persistent leucocyte influx.5 This suggests that at 
some stage during the development and progression 
of RA,12 immunomodulatory capability is lost, and 
a proinflammatory phenotype is acquired in syno-
vial fibroblasts. However, it remains unclear when 
these events occur. Here, we show for the first time 
that fibroblast–EC interactions evolve with disease 
progression and that fibroblasts at the earliest phase 
of RA exhibit a transitional functional phenotype 
that contributes to the accumulation of persistent 
infiltrates.
MAterIAls And MethOds
Isolation of human fibroblasts, ecs and 
lymphocytes
Synovial tissue samples were obtained by ultra-
sound-guided biopsy13 from treatment-naive 
patients with a new onset of clinically apparent 
arthritis and a symptom duration of ≤12 weeks, 
who at follow-up had either a resolving arthritis 
to cite: Filer A, 
Ward LSC, Kemble S, et al. 
Ann Rheum Dis published 
online First: [please include 
day Month Year]. doi:10.1136/
annrheumdis-2017-211286
handling editor tore K Kvien
 ► Additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2017- 211286).
1rheumatology research Group, 
Arthritis research UK Centre of 
Excellence in the pathogenesis 
of rheumatoid Arthritis, Institute 
of Inflammation and Ageing, 
Birmingham, UK
2department of rheumatology, 
Sandwell and West Birmingham 
Hospitals nHS trust, 
Birmingham, UK
3University Hospitals 
Birmingham nHS Foundation 
trust, Birmingham, UK
4Institute of Cardiovascular 
Sciences, University of 
Birmingham, Birmingham, UK
correspondence to
dr Helen M McGettrick, Institute 
of Inflammation and Ageing, 
University of Birmingham, 
Birmingham B15 2WB, UK;  
 h. m. mcgettrick@ bham. ac. uk
received 10 February 2017
revised 2 August 2017
Accepted 5 August 2017
 ARD Online First, published on August 28, 2017 as 10.1136/annrheumdis-2017-211286
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
group.bmj.com on November 1, 2017 - Published by http://ard.bmj.com/Downloaded from 
2 Filer A, et al. Ann Rheum Dis 2017;0:1–8. doi:10.1136/annrheumdis-2017-211286
Basic and translational research
(Res) or fulfilled RA classification criteria (very early RA; 
VeRA).14 Patients were classified as having resolving arthritis 
if there was no clinical evidence of synovial swelling at any 
peripheral joint (out of a swollen joint count of 66 joints) on 
final examination at least 1 year after initial presentation, in the 
absence of disease-modifying antirheumatic drugs (DMARD) or 
glucocorticoid therapy for at least the previous 3 months.15 In 
addition, synovial tissue samples were collected from subjects 
(A) with established, treated RA undergoing joint replace-
ment (JRep) surgery; or (B) undergoing exploratory arthros-
copy for unexplained joint pain with no macro or microscopic 
evidence of inflammation (non-inflamed—NI). RA was classified 
according to 2010 American College of Rheumatology criteria.16 
Prior to biopsy, the extent of greyscale synovitis and power 
Doppler enhancement within the synovium of the biopsied joint 
was systematically graded using a 0–3 scale.14 Fibroblasts were 
isolated as previously described17 and used between passages 
4 and 65.
Human umbilical vein EC were isolated from umbilical cords 
using collagenase as previously described.5 Peripheral blood 
lymphocytes from healthy individuals were isolated by centrifu-
gation on Histopaque 1077 (Sigma-Aldrich, Poole, UK) followed 
by panning on plastic.5 Lymphocytes were washed, counted and 
adjusted to a final concentration of 2×106/mL in M199 supple-
mented with 0.15% bovine serum albumin (BSA; Sigma) and 
35 µg/mL gentamycin (M199BSA).
All human samples were obtained with written, informed 
consent and approval from the Human Biomaterial Resource 
Centre (Birmingham, UK), West Midlands and Black Country 
Research Ethics Committee, North East Tyne and West South 
Research Ethics Committee, or University of Birmingham Local 
Ethical Review Committee in compliance with the Declaration 
of Helsinki.
lymphocyte recruitment to cocultures from flow
Endothelial-fibroblast cocultures were established on opposite 
sides of 0.4 µm pore Transwell filter inserts (BD Pharmingen, 
Cowley, UK) for 48 hours prior to treatment with or without 
100 U/mL tumour necrosis factor alpha (TNFα; R&D Systems, 
Abingdon, UK) and 10 ng/mL interferon gamma (IFNγ; Pepro-
tech, London, UK) for a further 24 hours as previously described.5 
In some experiments, neutralising antibodies against IL-6 (clone 
6708) or TGF-β1 (clone 9016; both 10 µg/mL; R&D Systems) 
were added alone or in combination when cocultures were estab-
lished.5 18 19 Neutralising antibodies were present throughout 
the coculture and cytokine stimulation. A flow-based adhesion 
assay5 (see online supplementary methods) was used to analyse 
lymphocyte recruitment from flow.
Gene expression analysis
Isolated EC mRNA5 (RIN≥7.80) was analysed by qPCR using 
Taqman Universal PCR Master Mix20 and Assay on Demand 
primer kits according to manufacturer’s instructions (Applied 
Biosystems, Warrington, UK). Samples were analysed using 
7900HT Real-Time PCR machine and SDS 2.4 (Applied Biosys-
tems), and expressed as 2−ΔCT relative to 18S.
Flow cytometry
Expression of intracellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) on cytokine-stim-
ulated EC mono and cocultures were analysed by flow cytom-
etry (see online supplementary methods). Data are expressed as 
median fluorescent intensity.
Quantification of soluble mediators
Soluble agents in culture supernatants were quantified using 
IL-6 DuoSet ELISA, sIL-6R Quantikine ELISA Kit or VersaMAP 
Luminex according to manufacturer's instructions (R&D 
Systems).
table 1 demographic and baseline p characteristics 
nI (n=11) resolving (n=14) VerA (n=11) Jrep (n=13)
Age (years)† 42 (34–47) 40 (32–66) 49 (48–60) 59 (39–62)
Female, n (%) 5 (45) 4 (29) 5 (45) 9 (69)
Symptom duration (weeks)† ‡ 6 (4–7) 6 (4–9) 1040 (780–1098)**, *****
DAS28 ESR at baseline§ ‡ 3.8±1.3 4.7±1.5 5.4±1.2*
ESR (mm/hour)† ‡ 9.5 (5–27) 25 (10–58) 37 (19–59)*
CRP (mg/L)† ‡ 8.5 (0–14) 26 (0–45) 32 (15–56)*
RF positive (%) ‡ 0 (0) 5 (45) 11 (85)**
ACPA positive (%) ‡ 0 (0)*** 7 (64) –
SJC28† ‡ 3 (2–6) 4 (3–9) 9 (4–14)
TJC28† ‡ 3 (1–6) 6 (3–13) 7 (2–12)
VAS† ‡ 41 (28–79) 46 (16–70) 64 (42–86)
US GS† ‡ 2 (1–2) 2 (2–3)**** ‡
US PD† ‡ 1 (0–1) 2 (0–2) ‡
NSAID (%) ‡ 9 (64) 7 (64) 8 (62)
Kruskal-Wallis test showed a significant effect of outcome group on DAS28 baseline, ESR, CRP (p<0.05), symptom duration and RF positive (p<0.001).
*p<0.05 and **p<0.01 compared with the resolving cohort by Dunn’s post-test; ***p<0.01 compared with the VeRA by Wilcoxon signed-rank test; ****p<0.01 compared 
with the resolving by Mann-Whitney U test; *****p<0.01 compared with the VeRA cohort by Dunn’s post-test. 
†Median (IQR).
‡Data not obtained from patients at time of presentation.
§Mean±SD.
ACPA, anticitrullinated protein antibody; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; JRep, joint replacement; NI, non-inflamed; 
NSAID, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; SJC28, 28 swollen joint counts; TJC28, 28 tender joint counts; US GS, ultrasound greyscale grade at the 
biopsied joint; US PD, ultrasound power Doppler grade at the biopsied joint; VAS, visual analogue scale; VeRA, very early RA.
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statistical analysis
Multivariant data were analysed using analysis of variance with 
Dunnett post-test or Kruskal-Wallis test with Dunn post-test. 
Alternatively, Mann-Whitney U test, Wilcoxon signed-rank 
test or unpaired t-test was performed. p<0.05 was considered 
as statistically significant.
results
demographic and baseline clinical characteristics of patients
The characteristics of the patients are shown in table 1. There 
was no significant difference in age, gender, 28 swollen joint 
counts, 28 tender joint counts, patient global visual analogue 
scale score, non-steroidal anti-inflammatory drug usage and 
ultrasound power Doppler score at the biopsied joint14 between 
clinical outcome groups. As expected, patients with RA under-
going joint replacement surgery had experienced symptoms for 
significantly longer than those with resolving synovitis and very 
Figure 1 Fibroblasts from patients with resolving and persistent arthritis differentially modulate lymphocyte recruitment from flow. Cocultures were 
established by culturing endothelial cells and fibroblasts on opposite sides of a porous insert, prior to treatment (A) without or (B) with TNFα+IFNγ for 
24 hours. Endothelial monolayers without fibroblasts (none) were used as controls. Lymphocytes were perfused and their interactions with endothelial 
cells were assessed by digital microscopy. (C, D) Micrograph images showing lymphocyte adhesion to (i) endothelial cells cultured alone, with 
fibroblasts from (ii) resolving, (iii) VeRA or (iv) JRep patients (C) in the absence of cytokine treatment and (D) in response to TNFα+IFNγ treatment. 
White arrow indicates an adherent lymphocyte. In A and B, Kruskal-Wallis test shows a significant effect of fibroblasts on lymphocyte adhesion 
(p<0.01). Data are the mean±SEM for n experiments; each incorporated a different donor for all three cell types. *p<0.05 and **p<0.01 by Dunn 
post-test. EC, endothelial cells; IFNγ, interferon gamma; JRep, joint replacement; NI, non-inflamed; Res, resolving; TNFα, tumour necrosis factor alpha; 
VeRA, very early RA.
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early RA. However, there was no difference in symptom dura-
tion between patients with resolving synovitis or very early RA. 
Patients with resolving disease had significantly lower DAS28 
(Disease Activity Score 28) erythrocyte sedimentation rate (ESR) 
at baseline, ESR and C-reactive protein when compared with 
patients undergoing joint replacement, but not those with very 
early RA. Patients with very early RA had a significantly higher 
ultrasound greyscale grade at the biopsied joint when compared 
with patients with resolving synovitis. Patients with resolving 
arthritis were diagnosed as having unclassified arthritis (n=6), 
parvovirus (n=3), reactive arthritis (n=2), pseudogout (n=1) 
and RA (n=2) according to established criteria. Of note, the 
two patients diagnosed with resolving RA had no evidence of 
joint-related soft tissue swelling on final examination. In both 
patients, synovitis resolved rapidly after briefly fulfilling criteria 
at presentation and no DMARDs were used in their treatment. 
All individuals with resolving arthritis were negative for rheuma-
toid factor and anticitrullinated protein antibody.
Fibroblasts from VerA lose an immunosuppressive phenotype 
before becoming proinflammatory
We have previously reported that fibroblasts from joints of 
patients with advanced RA directly induce leucocyte recruitment 
in the absence of exogenous cytokines.5 10 In this model, fibro-
blasts from patients with RA undergoing joint replacement, but 
not very early RA, significantly increased lymphocyte adhesion 
when compared with untreated EC monocultures (figure 1A). 
Moreover, in the absence of exogenous cytokines, similar levels 
of binding were observed when fibroblasts from non-inflamed, 
resolving or very early RA tissue were incorporated into cocul-
ture (figure 1A).
Using a model of inflammation where cultures were stimu-
lated with inflammatory cytokines, we examined the ability of 
synovial fibroblasts from different outcome groups to influence 
the cytokine-induced endothelial recruitment of lymphocytes. 
Fibroblasts from non-inflamed joints and resolving synovitis 
were immunosuppressive, inhibiting lymphocyte recruitment 
to TNFα+IFNγ-treated endothelium (figure 1B). By contrast, 
this effect was not observed when fibroblasts from patients with 
RA (either very early or longer duration disease) were incor-
porated into coculture. These fibroblasts no longer suppressed 
recruitment but rather supported lymphocyte adhesion at similar 
levels to those observed on cytokine-treated EC monocultures 
(figure 1B).
Collectively, these data indicate that fibroblasts from patients 
with very early RA are functionally distinct from both resolving 
synovitis and long-established disease, existing in a transitional 
state.
Unless otherwise stated, all future experiments were performed 
using cytokine-treated cocultures incorporating resolving or 
very early RA fibroblasts.
role of Il-6 and tGF-β1 in effects of resolving and very early 
rA fibroblasts in coculture
The immunosuppressive response of mesenchymal stromal cells 
from healthy tissues is facilitated by common bioactive media-
tors, IL-6 and TGF-β1.5 18 19 It is possible that such endogenous 
pathways are corrupted early in the pathogenesis of RA. Neutral-
isation of both IL-6 and TGF-β1 significantly blocked the inhib-
itory effects of resolving fibroblasts in coculture (figure 2A). In 
contrast, neutralisation of IL-6 and TGF-β1 in very early RA cocul-
tures significantly reduced lymphocyte adhesion (figure 2B), 
restoring immunoprotective functions to those of resolving 
Figure 2 Resolving fibroblasts mediated immunosuppressive effect 
through IL-6 and TGF-β1. Actions of IL-6 or TGF-β1 were neutralised, 
alone or in combination, in TNFα+IFNγ-treated cocultures incorporating 
fibroblasts from patients with (A) resolving synovitis, (B) very early RA or 
(C) joint replacement RA (JRep). Dotted line (-----) represents adhesion 
to TNFα+IFNγ-treated endothelial monocultures for paired experiments. 
IgG represents cocultures incubated with isotype control antibodies. In 
A and B, ANOVA shows a significant effect of antibody treatment on 
lymphocyte adhesion (p<0.01). Data are the mean±SEM from three to 
five independent experiments each incorporating a different donor for 
all cell types. *p<0.05 compared with None (untreated cocultures) by 
Dunnett post-test. ANOVA, analysis of variance; IFNγ, interferon gamma; 
IL-6, interleukin 6; JRep, joint replacement; RA, rheumatoid arthritis; 
TGF-β, transforming growth factor beta; TNFα, tumour necrosis factor 
alpha.
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cocultures. Interestingly, blockade of IL-6 and TGF-β1 had no 
effect on lymphocyte recruitment to cocultures incorporating 
RA fibroblasts from joint replacement patients (figure 2C). In all 
conditions, single antibody blockade or the presence of isotype 
antibodies had no effect on adhesion (figure 2A–C). Thus, IL-6 
and TGF-β1 had essentially opposite effects on cytokine-treated 
cocultures with either resolving or very early RA fibroblasts.
Exploring this further, we detected significantly more IL-6 in 
supernatants from cocultures compared with endothelial mono-
cultures following cytokine treatment (figure 3A). However, 
there was no difference between the clinical outcome groups 
(figure 3A). Of note, resting fibroblasts from different disease 
stages release comparable levels of IL-6 in culture (online supple-
mentary figure 1A). Soluble IL-6R transcripts in EC were also 
similar between all culture conditions tested (online supplemen-
tary figure 1B); however, we were unable to detect measurable 
levels of sIL-6R released by these cultures. Suppressor of cyto-
kine signalling 3 (SOCS3) and SOCS1 regulate signal transducer 
and activator of transcription (STAT) activation in response to 
IL-6.21 Here, expression of SOCS3 was upregulated in EC from 
resolving cocultures, but not in EC from very early RA cocul-
tures (figure 3B). In contrast, SOCS1 expression in EC remained 
unchanged upon coculture (figure 3C). Downstream signalling 
from IL-6 differed between the two forms of cytokine-activated 
cocultures.
Profile of secretome released by resolving and VerA 
fibroblasts in coculture
We also wondered whether very early RA fibroblasts altered 
the secretome generated during coculture, such that it was 
no longer immunosuppressive. Using multiplex analysis, we 
detected significantly higher levels of the chemokines CXCL10 
and IL-8, and a tendency for higher CXCL5 in the very early 
RA coculture supernatants when compared with the resolving 
cocultures (figure 4A–C). However, expression of the chemo-
kines CXCL1, CCL5 and CCL2 was comparable between both 
coculture conditions (figure 4D–F), while IL-4, IL-10 and IL-1α 
were undetectable. We observed no significant difference in the 
concentration of these chemokines released by resolving and 
very early RA monocultures, although overall levels were lower 
than that found in cocultures (online supplementary figure 2). 
Therefore, the composition, and potentially the bioactivity, of 
the secretome appeared to differ between resolving and very 
early RA cocultures.
Analysis of gene expression in ec upon coculture
To further investigate the loss of suppression of lymphocyte 
adhesion, we analysed the expression of adhesion molecules and 
chemokines by inflamed EC upon coculture. Comparing EC from 
resolving and very early RA cocultures, we detected no difference 
in the expression of ICAM-1 or VCAM-1 (online supplementary 
figure 3), or CXCR3 ligand transcripts (data not shown). While 
coculture significantly reduced expression of E-selectin mRNA 
compared with cytokine-treated EC alone (data not shown), this 
effect was similar for each disease outcome. Thus, changes in the 
expression of the genes analysed showed no clear differences 
between disease outcomes or correlation with the functional 
differences in recruitment observed with resolving and very early 
RA cocultures.
dIscussIOn
Little is known about how the development of RA alters the 
immunomodulatory properties of synovial fibroblasts. We 
Figure 3 Secretion and signalling of IL-6 in cocultures. (A) IL-6 release 
during TNFα+IFNγ-treated cocultures. ANOVA shows a significant effect 
of culture conditions on the secretion of IL-6 (p<0.001). (B) SOCS3 and 
(C) SOCS1 gene expression analysed by qPCR. Data are expressed as 
2−ΔCT relative to 18S expression. Data are the mean±SEM from three 
to five independent experiments each incorporating a different donor 
for all cell types. *p<0.05, **p<0.01 and ***p<0.001 compared with 
None (endothelial monoculture) by Dunnett post-test, unless otherwise 
indicated. ANOVA, analysis of variance; IFNγ, interferon gamma; IL-6, 
interleukin 6;  JRep, joint replacement; Res, resolving; SOCS, suppressor 
of cytokine signalling; TNFα, tumour necrosis factor alpha; VeRA, very 
early RA.
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examined for the first time the effects of phase of disease and 
disease outcome on synovial fibroblast regulation of the inflam-
matory infiltrate through crosstalk with EC. Synovial fibroblasts 
show outcome-specific and stage-specific effects. Upon cocul-
ture with EC, fibroblasts from resolving synovitis suppressed 
lymphocyte adhesion in response to cytokines. This immu-
noprotective effect was lost in fibroblasts from very early RA, 
allowing increased lymphocyte recruitment. Hence, fibroblasts 
cultured from tissues with divergent disease outcomes (resolving 
vs persistence) are functionally distinct. Moreover, fibroblast–
EC interactions evolve with RA progression. In contrast to 
established disease, fibroblasts from very early RA have not yet 
acquired the ability to autonomously activate EC in the absence 
of exogenous cytokines. Thus, we have shown for the first time 
that synovial fibroblasts undergo two distinct functional changes 
as RA evolves: first the early loss of immunosuppressive capa-
bility, and second the slower acquisition of an intrinsically stim-
ulatory phenotype during disease progression.
IL-6 and TGF-β are pleiotropic cytokines, each able to 
induce divergent proinflammatory or anti-inflammatory effects 
depending on the inflammatory context or cell type (reviewed 
by ref 1). Moreover, emerging evidence reveals complex and 
intricate crosstalk between IL-6 and TGF-β1 signalling pathways, 
in which each cytokine can positively22–24 or negatively25–27 
regulate the expression or activity of the other depending on 
the inflammatory context. Using T cell biology as an example, 
TGF-β1 inhibited the production of the IL-6 inhibitor SOCS3, 
thus prolonging IL-6 signalling to initiate Th17 differentiation.28 
Conversely, IL-6 augmented expression of the TGF-β signalling 
inhibitor SMAD7, preventing TGF-β1-induced TReg differentia-
tion.26 In the context of leucocyte recruitment, treatment with 
recombinant IL-6 or TGF-β1 or both suppressed neutrophil 
infiltration into lipopolysaccharide (LPS)-inflamed lungs.29 Such 
apparently divergent, contextually determined roles are seen in 
our study. Here, IL-6 and TGF-β1 were identified as the bioactive 
agents required for the inhibitory effects on recruitment of cocul-
tured resolving fibroblasts. Similar findings have been reported 
for stromal cells from non-inflamed tissues,5 18 suggesting the 
existence of shared stromal immunoprotective mechanisms. In 
contrast, neutralisation of IL-6 and TGF-β1 inhibited the prore-
cruitment effect of cocultured very early RA fibroblasts. This 
suggests that in VeRA, IL-6 and TGF-β1 have not simply lost effi-
cacy, but trigger stimulatory rather than inhibitory downstream 
events.
Synovial fibroblasts are a major source of IL-6 in RA,30 which 
we also observed in our EC-fibroblast cocultures. IL-6 can 
signal through its membrane-bound (CD126; IL-6R) or soluble 
receptor (sIL-6R) (reviewed by ref 31). Indeed, synovial fibro-
blasts induce STAT3 phosphorylation and activation in response 
to sIL-6R engagement.32–34 The absence of detectable sIL-6R in 
our supernatants (both measured here and previously10) strongly 
indicates that IL-6 released during coculture signals through 
CD126 expressed by EC,5 but not fibroblasts. Given that 
fibroblasts cannot respond to IL-6 generated during coculture, 
distinct fibroblast–EC interactions must regulate EC responses 
to IL-6 and produce the discrete patterns of lymphocyte recruit-
ment that we observed. Here, we observed two different patterns 
of expression of the negative regulator, SOCS3, in EC from 
resolving and very early RA cocultures. We hypothesise that high 
SOCS3 expression (ie, negative regulation of STAT activation), 
as seen in the EC from resolving cocultures, triggers an immu-
noprotective IL-6 response. Conversely, failure to induce SOCS3 
was associated with loss of immunosuppressive responses in the 
EC from very early RA cocultures. Such a situation has been 
Figure 4 Secretome from resolving and very early RA cocultures. Conditioned media from resolving or very early RA fibroblast cocultures were 
measured by multiplex analysis. (A) CXCL10, (B) IL-8, (C) CXCL5, (D) CXCL1, (E) CCL5 and (F) CCL2 expression. Data are the mean±SEM from five to 
nine independent experiments each incorporating a different donor for all cell types. *p<0.05 by unpaired t-test. IL-8, interleukin 8, also known as 
CXCL8; Res, resolving; VeRA, very early RA.
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observed in adjuvant-induced arthritis, where low endothelial 
SOCS3 levels, and therefore negative regulation of IL-6 signal-
ling, has been linked with more severe arthritis and elevated 
neutrophil influx into the joint.35 Collectively, these data reveal 
two distinct IL-6 signalling pathways in EC from cocultures, 
which are induced in a disease outcome-specific manner and 
elicit different functional consequences in EC.
Our data clearly show that IL-6 acts synergistically with 
TGF-β1 to mediate the differential effects on lymphocyte adhe-
sion to inflamed EC in coculture. TGF-β1 is secreted in its 
bioactive form by a variety of cell types, including EC and fibro-
blasts. However, the ELISA kits available during this study only 
measured total TGF-β1 after acid activation, rather than bioac-
tive TGF-β1. Therefore, it is not possible to distinguish which 
cell type was secreting bioactive TGF-β1. EC in all conditions 
expressed similar transcript levels of the three TGF-β receptors 
(data not shown), indicating that EC were potentially capable 
of responding to TGF-β1 produced during coculture. The 
requirement to understand the inflammatory context of TGF-β1 
production is once again emphasised by conflicting findings 
on the impact (suppressive36 vs stimulatory37) of TGF-β1 on in 
vivo models of arthritis, where exogenous TGF-β1 treatment 
either exacerbated,38 39 alleviated40 or had no effect41 on disease 
severity.
Biological therapies that target IL-6 and its receptor (eg, 
tocilizumab) are efficacious in RA including for those individ-
uals who do not respond to anti-TNFα treatment.42 43 Although 
we detected similar concentrations of IL-6 in cocultures, we 
did observe a different profile of soluble mediators released by 
resolving and very early RA fibroblast cocultures. This raises 
the intriguing possibility that the bioactivity of the secretome 
is different between the two cocultures, where soluble agents 
exclusive to the very early RA cocultures alter IL-6 and TGF-β1 
responses to generate a stimulatory effect. Moreover, difference 
in the secretomes by resolving and very early RA cocultures 
could influence the presentation of chemokines by the endothe-
lium and therefore might account for the altered lymphocyte 
adhesion profiles observed here. For example, fibroblast-in-
duced production of proteases during coculture can adversely 
affect lymphocyte binding.44 Further work is required to identify 
the exact soluble mediator(s) responsible for these changes, as 
they are likely to offer novel targets for early therapeutic inter-
vention in RA.
Failure to suppress recruitment may represent a manifes-
tation of the transition the stroma undergoes as the disease 
progresses. It is unlikely that such changes in very early RA are 
due to the fibroblasts passively responding to local inflamma-
tory responses. Instead, fibroblasts with a transitional functional 
phenotype will actively contribute to disease development and 
persistence, further fuelling the evolution of their phenotype 
towards so-called ‘imprinted aggressors’ (eg, ref 45). Emerging 
evidence strongly indicates such reprogramming is due to accu-
mulated epigenetic modifications,46 47 which may directly alter 
the production of proinflammatory mediators or modify the 
balance of microRNAs (eg, mir155, 146, 203) within the fibro-
blast.(e.g, ref 48) This could explain how the regulation of IL-6 
mRNA stability becomes altered in rheumatoid synovial fibro-
blasts, where the negative regulator Zc3h12a (RNA-binding 
protein) switches its activity to positively stabilise IL-6 mRNA.49 
Epigenetic modifications in the earliest phases of disease could 
also account for the differential effects seen in this study by 
resolving and VeRA fibroblasts in coculture.
Our study is not the first to indicate that Vvery early RA is 
subtly different from resolving arthritis or established RA. 
Patients with very early disease have a distinct serum metabo-
lomic profile and synovial fluid cytokine profile when compared 
with patients with established RA.15 50 Moreover, fibroblasts 
from very early RA showed increased dickkopf-related protein 
1 (DKK-1) expression with the potential to adversely alter bone 
remodelling; a feature not apparent in fibroblasts from patients 
with resolving synovitis.51 Collectively, these data strongly 
support the transitional nature of synovial pathology during 
the earliest stages of disease development. Early interventions 
targeting ‘pathogenic’ fibroblasts may therefore be required in 
order to restore protective regulatory processes.
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